TECX
Tectonic Therapeutic, Inc.
NASDAQ · Healthcare · Biotechnology · US
$21.15
+2.42%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$21.27
From 52W high−44.24%
Volume202963.00
Market cap$413.47M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$21.27
From 52W high
−44.24%
Volume
202963.00
Market cap
$413.47M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.3x
P/E (TTM)
—
RSI (14)
28.9
MomentumView details →
1D Return
+2.42%
YTD Return
+0.05%
SummaryUpdated Jun 1, 2026
Tectonic Therapeutic, Inc. (NASDAQ:TECX) is a clinical-stage biotechnology company founded to develop innovative therapeutic proteins and antibodies targeting G-protein coupled receptors (GPCRs). Based in Watertown, Massachusetts, the company has built its operations around its proprietary GEODe technology platform, which enables the discovery and development of GPCR-targeted biologic medicines. As a pre-revenue biotechnology company, Tectonic is currently advancing multiple drug candidates through clinical trials, with its lead program focused on heart failure treatment entering Phase 1 studies.
Similar companies
Latest newsMore news →
Tectonic Therapeutic announced favorable Phase 1a topline safety, tolerability and pharmacokinetic results for TX2100, an investigational antibody for hereditary hemorrhagic telangiectasia, and plans to start a Phase 1b trial by year-end 2026 and a Phase 2 trial in early 2027.20d agoTectonic Therapeutic completed enrollment in the TX45 APEX Phase 2 clinical trial for PH-HFpEF patients.131d ago